If you have been reading about TB-500 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-12. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Ventral developmental patterning and the expression of transcription factors is influenced by the gradients of BMP2 and sonic hedgehog protein (SHH). These factors are essential for coordinating early patterns of cell proliferation. Six weeks into gestation, the corticotroph cells can be identified. By seven weeks of gestation, the anterior pituitary is capable of secreting ACTH. Within eight weeks of gestation, somatotroph cells begin to develop with cytoplasmic expression of human growth hormone. Once a fetus reaches 12 weeks of development, the thyrotrophs begin expression of Beta subunits for TSH, while gonadotrophs being to express beta-subunits for LH and FSH. Male fetuses predominately produced LH-expressing gonadotrophs, while female fetuses produce an equal expression of LH and FSH expressing gonadotrophs. At 24 weeks of gestation, prolactin-expressing lactotrophs begin to emerge.
Theranostics, or theragnostics, refers to the combination of diagnosis and therapy (treatment) of disease in a single medical intervention or technique. For example, a combination of radioactive isotopes may be administered to simultaneously image and treat cancerous lesions. Typically theranostic approaches involve a medical imaging component, such as radiotracers, contrast agents, positron emission tomography, and magnetic resonance imaging. The term "theranostic" is a portmanteau of two words, therapeutic and diagnostic. The first known use of the term is attributed to John Funkhouser, a consultant for the company Cardiovascular Diagnostic, who used it in a press release in August 1998. Nanotheranostics is the specialization of theranostics in the nanoscale.
== Early life and education == Born in Kent, the daughter of Denis E. Bradley and Lillian (née Holder), Carol Vivien Bradley left school at 16 and began her career as a lab technician in Sandwich, Kent with Pfizer, where she began working with the then novel technique of mass spectrometry. Her potential was spotted, and she gained further qualifications at evening classes and day release from her job at Pfizer. After earning her degree, she left Pfizer and studied for a Master of Science degree at the University of Swansea, followed by a Ph.D. at the University of Cambridge, which she completed in just two years. During this time she was a student at Churchill College, Cambridge.
== History == Transaid was founded in 1998 by Save the Children, the Chartered Institute of Logistics and Transport (CILT), and its patron, Anne, Princess Royal. It is a UK‑based international development charity focused on transforming lives through safe, available, and sustainable transport in sub‑Saharan Africa. The charity operates multiple programmes in several countries, working with governments, communities, and industry partners to improve road safety, transport management, and access to healthcare. In recent years, Transaid has been active in motorcycle helmet safety in Kenya through its Kenya National Helmet Wearing Coalition, working with the FIA Foundation and others to build enforcement of helmet standards, establish awareness among riders, and to set up a helmet testing laboratory in East Africa. The charity has also launched its Christmas Appeal 2025 to raise funds from individuals and businesses for road safety and healthcare access across sub‑Saharan Africa; in that appeal, it reported having trained over 9,000 professional drivers and riders, delivered thousands of eye tests, and supported minibus‑taxis adopting safety charters. Additionally in early 2025, Princess Anne opened the new London office of Arbuthnot Latham, a corporate partner of Transaid, emphasising the strengthening of corporate backing and visibility for the charity.
==== Mount Koya ==== It was developed by Mokujiki Shonin, a Shingon priest in the early 1600s during the Edo Period. He encouraged all the mountain temples to make their own tofu after he obtained large amounts of soybeans from the head Shingon temple. The purpose of this was to preserve some of the frozen tofu until the Spring equinox. Firm tofu was left outdoors in the cold windy night to freeze. After it was frozen, it was allowed to stand on shelves in a shed for fifteen days at temperatures below freezing, thawed in warm water and pressed lightly to expel the melted ice, then dried in the shed using heat from charcoal braziers.
Sources: en.wikipedia.org
== Applications == Because of its ability to cause chemical reactions and excite fluorescence in materials, ultraviolet radiation has a number of applications. The following table gives some uses of specific wavelength bands in the UV spectrum.
The emperor was dressed in his interment attire: the court dress uniform of a Marshal of the Imperial Brazilian Army, with the star of the Imperial Order of the Cross on his chest. He also wore the Order of the Golden Fleece and the collar of the Imperial Order of the Rose, while his hands clutched a silver crucifix sent by Pope Leo XIII. Despite recognizing the body's overall preservation, however, d'Escragnolle Dória felt that the embalming had not fully succeeded in maintaining the emperor's appearance. He wrote: His face resembles old wax. His beard, once so fine, silky, and white, has turned a dull yellow, like aged ivory. When I saw him in February 1912, I found him smaller than he had been in late 1909. The head of Dom Pedro II rests on a pillow filled with Brazilian soil. The emperor looks so different! How cruel is an imperfect embalming! Where is that majestic head, once crowned with silvery hair? Where are his steel-blue eyes, his beautiful beard—gilded by youth and silvered by age—and his stately bearing? Everything is gone, faded!
== Uses == Pure ammonium formate decomposes into formamide and water when heated, and this is its primary use in industry. Formic acid can also be obtained by reacting ammonium formate with a dilute acid, and since ammonium formate is also produced from formic acid, it can serve as a way of storing formic acid. Ammonium formate can also be used in palladium on carbon (Pd/C) reduction of functional groups. In the presence of Pd/C, ammonium formate decomposes to hydrogen, carbon dioxide, and ammonia. This hydrogen gas is adsorbed onto the surface of the palladium metal, where it can react with various functional groups. For example, alkenes can be reduced to alkanes, formaldehyde to methanol, and nitro compounds to amines. Activated single bonds to heteroatoms can also be replaced by hydrogens (hydrogenolysis). Ammonium formate can be used for reductive amination of aldehydes and ketones (Leuckart reaction), by the following reaction:
As part of the in-universe viral marketing campaign, a series of video segments for the series started to be released in the form of in-universe news reports from Vought News Network—a parody of the Cable News Network (CNN) as well as Fox News—called Vought News Network: Seven on 7 with Cameron Coleman through the Vought International YouTube channel. The video segments were released on the seventh day of each month over a period of seven months starting on July 7, 2021, and concluding on January 7, 2022. The video segments served as a bridge between seasons two and three, with each segment containing different stories that tease a series of events expected to happen on upcoming episodes and introducing new characters. Matthew Edison joined the series as Vought News Network anchor Cameron Coleman, a role that he would reprise in the series' third and fourth seasons. The character has also been reported to be a parody of Tucker Carlson. On May 13, 2022, it was released a faux poster for the in-universe fictional film Payback with every member of the superhero group in it with Soldier Boy at the front and center of the poster and the other members surrounding him from behind, serving as a parody and reference of The Avengers film series.
== Consumption == The largest fruit juice consumers are New Zealand (nearly a cup, or 8 ounces, each day) and Colombia (more than three quarters of a cup each day). Fruit juice consumption, on average, increased with country income level. In 2007, a report stated that fruit juice consumption overall in Europe, Australia, New Zealand, and the US had increased in recent years. In 2015, people in the United States consumed approximately 6.6 US gallons of juice per capita, with more than half of preschool-age children being regular drinkers.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.